Study Group: Prescribers of Combivir : HIV Specialists (EU)(?)
Council Members in this Study Group: 15
Request a survey with this Study Group
Related Study Groups
| Study Group Name | Members |
|---|---|
| HIV Specialists (EU) | 115 |
| Infectious Disease Specialists (EU) | 342 |
| Physicians (Germany) | 1148 |
| Physicians who Treat HCV (EU) | 29 |
| Infectious Disease Physicians (UK) | 70 |
| Cubicin Prescribers (US) | 173 |
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
The HLAB5701 test is inexpensive and uncomplicated to perform It reduces risk of the hypersenitivity reaction. Two recent studies have raised concerns about abacavir. -ACTG 5202 study has indicated that in persons with high viral loads epzicom (the main brand of abacavir)...
Impressive 7 day antiviral effects Potential for QD naive and BD experienced approaches Potential for coformulations Revised formulation moving into next phase of testing No critical safety issues in volunteers or patients Metabolit may be anti-gout agent
Very Good News For HIV Infected Individuals. Sandro Vento, MD. Azienda Ospedaliera di Cosenza, Italy
Atripla is a fixed combination in a single pill of three excellent antiretroviral drugs with very good pharmacokinetics profile and fairly good tolerability. It will have a considerable impact on compliance as it can be taken once daily. If compliance will be as good as predictable, the chances that...
While ideally Maraviroc would now be approved the requests from the FDA do not require new clinical trials. The main issues relate to the failings of other drugs in this class Aplaviroc (Ono/GSK) discontinued for hepatotoxicity and questions over malignancies with Vicriviroc (Schering-Plough). Data...
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Academic Institution*
- Facility, Academic Medical Center
- Non-Academic Community Hospital or Clinic
Most Common Job Types:
- Physician - Attending Physician
- Physician - Director
- Physician - Division Head
- Professor
- Director